Compare UPLD & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | EVAX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 31.9M |
| IPO Year | 2014 | 2020 |
| Metric | UPLD | EVAX |
|---|---|---|
| Price | $0.71 | $3.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.75 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 374.8K | 32.1K |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.50 | $1.20 |
| 52 Week High | $3.90 | $12.15 |
| Indicator | UPLD | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 55.05 |
| Support Level | $0.51 | $2.45 |
| Resistance Level | $1.62 | $4.64 |
| Average True Range (ATR) | 0.07 | 0.39 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 68.98 | 54.62 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.